Japan’s general trading houses are steadily becoming a force to be reckoned with in the pharmaceutical industry — and not…
HOME > BUSINESS
BUSINESS
- Novartis’ Compliance Advisory Board Holds 1st Meeting amid Diovan Fuss
November 21, 2013
- JT’s Anti-HIV Agent Elvitegravir Wins European Regulatory Approval
November 21, 2013
- Bristol-Myers Italy Head Piras Sworn in as Japan President
November 21, 2013
- Shionogi Licenses 2 Oxycodone Products with Abuse-Deterrent Measures from Mundipharma
November 21, 2013
- US Pfizer Plans Simultaneous, Global Filing of Five Biosimilars, Eyes Japan Biosimilar Market Entry
November 20, 2013
- Nichi-Iko to Collaborate with Hanoi Pharmaceutical of Vietnam
November 20, 2013
- Takeda, Eisai Earnings Show Signs of Bottoming Out, on Path to Recovery
November 18, 2013
- CMIC Chairman Sorry for Alleged Clinical Data Tampering; Probe Report Due out Late November
November 18, 2013
- PIII Study of Brexpiprazole Starts in US and Europe for Treatment of Agitation in AD: Otsuka Holdings
November 18, 2013
- Sales of Major Japanese Drug Makers Soar 8.1% on Weak Yen, Steady Japan Business
November 15, 2013
- Chugai Puts Off NHI Price Listing for Kadcyla, Agreement Not Reached
November 15, 2013
- Otsuka Holdings Notches Double-Digit Sales Growth in April-September, Weaker Yen Comes as Boon
November 14, 2013
- Chugai Obtains Exclusive Commercialization Rights for Anamorelin in Europe from Helsinn
November 14, 2013
- Kenko.com Sues Government to Affirm Right to Sell Prescription Drugs Online
November 14, 2013
- Generic Market Continues to Grow, Three Generic-Only Makers’ Sales Up 8.8%
November 13, 2013
- Kyowa Kirin Ceases Japan PII Trial on Chronic Kidney Disease Agent
November 13, 2013
- JV of DSP, Japan BCG to Develop New TB Vaccines with NIBIO, US NPO
November 13, 2013
- Antiepileptic Drug Eslicarbazepine Granted US Approval: DSP
November 13, 2013
- Commercial Director Feliciano to Become President of Merck Serono Japan
November 12, 2013
- Eylea Bests Lucentis in Ophthalmic VEGF Inhibitor Market; Santen Ups Sales Outlook for Drug
November 12, 2013
ページ
A public-private council report outlining industry views on Japan’s drug pricing systems drew little discussion at a meeting of the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
In the complex tapestry of leadership, awareness isn’t just a desirable trait; it’s the bedrock upon which success is built. It’s the lens through which leaders perceive, interpret, and navigate the ever-shifting landscape of their organizations and industries. Without it,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…